Interaction between potential doubling time and TP53 mutation:: Predicting radiotherapy outcome in squamous cell carcinoma of the head and neck

被引:16
作者
Alsner, J [1 ]
Hoyer, M [1 ]
Sorensen, SB [1 ]
Overgaard, J [1 ]
机构
[1] Aarhus Univ Hosp, Dept Expt Clin Oncol, Danish Canc Soc, DK-8000 Aarhus C, Denmark
来源
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS | 2001年 / 49卷 / 02期
关键词
tumor potential doubling time; Tpot; TP53; mutation; radiotherapy; predictive factor; head and neck cancer;
D O I
10.1016/S0360-3016(00)01489-9
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose: To investigate the correlation between tumor potential doubling time, Tpot, and mutations in the p53 gene, TP53, and the potential of these parameters to predict outcome of head and neck cancer patients treated with radiotherapy. Methods and Materials: Data from two independent studies on Tpot and TP53 mutations were combined, including 58 patients with squamous cell carcinoma of the head and neck, Tpot was estimated on biopsies obtained 6-9 h after infusion of iododeoxyuridine by combined flow cytometry and immunohistology. TP53 mutations were detected using DGGE and sequenced. All patients received primary radiotherapy alone. Results: The predictive value of Tpot alone was of borderline significance, However, in TP53 wild-type tumors, Tpot was a strong predictor of outcome, whereas Tpot in TP53 mutant tumors failed to provide any information. Tpot and TP53 were not associated with nodal control; however, there was a strong relationship with control in the T-position, disease-specific survival, and overall survival. Conclusion: Tpot can to be a relevant parameter for predicting outcome of radiotherapy in head and neck cancer but only in the subset of patients without mutations in the p53 gene. (C) 2001 Elsevier Science Inc.
引用
收藏
页码:519 / 525
页数:7
相关论文
共 27 条
[1]  
ALSNER J, UNPUB RADIOTHER ONCO
[2]   The value of pretreatment cell kinetic parameters as predictors for radiotherapy outcome in head and neck cancer: a multicenter analysis [J].
Begg, AC ;
Haustermans, K ;
Hart, AAM ;
Dische, S ;
Saunders, M ;
Zackrisson, B ;
Gustaffson, H ;
Coucke, P ;
Paschoud, N ;
Hoyer, M ;
Overgaard, J ;
Antognoni, P ;
Richetti, A ;
Bourhis, J ;
Bartelink, H ;
Horiot, JC ;
Corvo, R ;
Giaretti, W ;
Awwad, H ;
Shouman, T ;
Jouffroy, T ;
Maciorowski, Z ;
Dobrowsky, W ;
Struikmans, H ;
Rutgers, D ;
Wilson, GD .
RADIOTHERAPY AND ONCOLOGY, 1999, 50 (01) :13-23
[3]   The p53 gene as a modifier of intrinsic radiosensitivity: Implications for radiotherapy [J].
Bristow, RG ;
Benchimol, S ;
Hill, RP .
RADIOTHERAPY AND ONCOLOGY, 1996, 40 (03) :197-223
[4]   A randomised multicentre trial of CHART versus conventional radiotherapy in head and neck cancer [J].
Dische, S ;
Saunders, M ;
Barrett, A ;
Harvey, A ;
Gibson, D ;
Parmar, M .
RADIOTHERAPY AND ONCOLOGY, 1997, 44 (02) :123-136
[5]   TP53 DNA contact mutations are selectively associated with allelic loss and have a strong clinical impact in head and neck cancer [J].
Erber, R ;
Conradt, C ;
Homann, N ;
Enders, C ;
Finckh, M ;
Dietz, A ;
Weidauer, H ;
Bosch, FX .
ONCOGENE, 1998, 16 (13) :1671-1679
[6]  
Fu K. K., 1999, International Journal of Radiation Oncology Biology Physics, V45, P145, DOI 10.1016/S0360-3016(99)90019-6
[7]  
Gallo O, 1999, INT J CANCER, V84, P573, DOI 10.1002/(SICI)1097-0215(19991222)84:6<573::AID-IJC6>3.0.CO
[8]  
2-R
[9]  
Guldberg P, 1997, HUM MUTAT, V9, P348, DOI 10.1002/(SICI)1098-1004(1997)9:4<348::AID-HUMU8>3.3.CO
[10]  
2-7